BioCardia Enrolls First Patient in Phase III Trial

An announcement from BioCardia ( (BCDA) ) is now available.

On May 1, 2025, BioCardia announced the enrollment of the first patient in the Phase III CardiAMP HF II clinical trial at BayCare Morton Plant Hospital in Florida. This trial aims to confirm the safety and efficacy of its lead autologous cell therapy for heart failure, potentially impacting regulatory approvals and adoption. The trial builds on previous promising results, with advancements in patient eligibility and delivery systems, and is supported by the Maryland Stem Cell Research Fund and CMS reimbursement.

Spark’s Take on BCDA Stock

According to Spark, TipRanks’ AI Analyst, BCDA is a Neutral.

BioCardia’s stock score reflects significant financial challenges and negative valuation metrics. However, technical indicators suggest potential short-term gains, and recent corporate events and trial results offer some optimism for future growth. The earnings call highlighted improvements but also underscored persistent risks.

To see Spark’s full report on BCDA stock, click here.

More about BioCardia

BioCardia, Inc., headquartered in Sunnyvale, California, is a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases. The company offers biotherapeutic platforms such as CardiAMP® autologous and CardiALLO™ allogeneic cell therapies, supported by its Helix™ biotherapeutic delivery and Morph® vascular navigation product platforms.

YTD Price Performance: 38.94%

Average Trading Volume: 76,151

Technical Sentiment Signal: Buy

Current Market Cap: $14.7M

Find detailed analytics on BCDA stock on TipRanks’ Stock Analysis page.